Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Price Down 5.6% – What’s Next?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares dropped 5.6% during trading on Tuesday. The company traded as low as $12.35 and last traded at $12.60. 6,393 shares traded hands during trading, a decline of 96% from the average daily volume of 145,575 shares. The stock had previously closed at $13.35.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The company has a market capitalization of $28.53 billion, a price-to-earnings ratio of 16.03 and a beta of 0.62. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.41. The company’s 50 day simple moving average is $13.18 and its 200-day simple moving average is $12.41.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. On average, equities research analysts predict that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.